In an op-ed published Friday, Sabin president Peter Hotez, M.D., Ph.D., and his Baylor College of Medicine colleague, William Brinkley, Ph.D., applaud the dramatic gains Texas institutions have made to become leaders among the global scientific community. They cite the routinely high ranking of public and private Texas universities as well as a voter approved amendment to start the Cancer Prevention and Research Institute of Texas (CPRIT).

Financing research and development (R&D) for neglected tropical disease (NTDs) is a big challenge. The problem? Market failure.

NTD control is also important for success in fighting other important diseases – notably HIV/AIDs, tuberculosis and malaria.  In Africa, there are high rates of co-infection among NTDs and HIV/AIDs, tuberculosis and malaria, demonstrating an increased need for more research to unlock the links b

This article, written by Dr. Peter Hotez, president of Sabin Vaccine Institute and dean of the National School of Tropical Medicine at Baylor College of Medicine, originally appeared in TAMEST (The Academy of Medicine, Engineering and Science of Texas) e-news.
A paper co-authored by Sabin president Dr. Peter Hotez and published today inPLoS Neglected Tropical Diseases reports on the disease burden of neglected tropical diseases (NTDs) in India and South Asia. The press release below describes some of the significant findings from the study and also suggestions from the authors about how to control NTDs in the region.

Great news in the world of global health! A recent clinical trial for an experimental malaria vaccine has yielded successful results in protecting a large number of children against malaria with minimal side effects.

ABC News posted a video Thursday entitled “Parasitic Worms,” which features Sabin Vaccine Institute’s Dr. David Diemert discussing Sabin Vaccine Development work in Minas Gerais, Brazil. The video, which was produced in 2010 by Rockhopper, highlights the pervasiveness of hookworm infection among children in Brazil.

In partnership with the Fraunhofer Center for Molecular Biotechnology and the Walter Reid Army Institute for Research, the Sabin Vaccine Institute has successfully expressed the hookworm-derived antigen Na-APR-1.